Related content

In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin)

By Ryu Jung   Lee Hong   Hong Young-Soo   Lee Jung   Sohn Uy   Kim Tae  

Cancer Chemotherapy and Pharmacology, Vol. 57, Iss. 6, 2006-06 ,pp. : 811-818

Springer Publishing Company

Access to resources Recommend Favorite

Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models

By Lee Hong   Ryu Jung   Jeon Yong-Jin   Hong Young-Soo   Lee Jung   Hong Soon-Kwang   Kim Tae-Yong  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 197-201

Springer Publishing Company

Access to resources Recommend Favorite

Anthracycline cardiotoxicity and lymphoma

By Mayr David   Fridrik Michael A.  

memo - Magazine of European Medical Oncology, Vol. 7, Iss. 1, 2014-02 ,pp. : 43-46

Springer Publishing Company

Access to resources Recommend Favorite

X609, a novel manassantin A derivative, exhibits antitumor activity in MG-63 human osteosarcoma cells in vitro and in vivo

By            

Molecular Medicine Reports, Vol. 12, Iss. 2, 2015-01 ,pp. : 3115-3120

Spandidos Publications

Access to resources Recommend Favorite

Anthracycline-induced chronic cardiotoxicity and heart failure

By Appel Jon M.   Nielsen Dorte   Zerahn Bo   Jensen Benny V.   Skagen Knud  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 576-580

Informa Healthcare

Access to resources Recommend Favorite